Fresenius SE & Co KGaA (FRE) Given a €88.10 Price Target by Berenberg Bank Analysts

Berenberg Bank set a €88.10 ($108.77) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the stock.

FRE has been the topic of several other research reports. Goldman Sachs set a €71.00 ($87.65) price target on Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Monday, February 19th. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Friday, March 2nd. UBS set a €59.00 ($72.84) price target on Fresenius SE & Co KGaA and gave the stock a sell rating in a report on Friday, January 5th. Warburg Research set a €80.00 ($98.77) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Thursday, December 21st. Finally, Citigroup set a €83.00 ($102.47) price target on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of €77.69 ($95.91).

How to Become a New Pot Stock Millionaire

FRE opened at €64.46 ($79.58) on Monday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($74.27) and a 12-month high of €80.00 ($98.77).

WARNING: “Fresenius SE & Co KGaA (FRE) Given a €88.10 Price Target by Berenberg Bank Analysts” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/17/fresenius-se-88-10-price-target-by-berenberg-bank-analysts.html.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply